PMID- 12166042
OWN - NLM
STAT- MEDLINE
DCOM- 20020918
LR  - 20190222
IS  - 1079-2082 (Print)
IS  - 1079-2082 (Linking)
VI  - 59
IP  - 15
DP  - 2002 Aug 1
TI  - Tinzaparin sodium: a low-molecular-weight heparin.
PG  - 1426-36
AB  - The chemistry, pharmacokinetics, pharmacodynamics, clinical efficacy, dosage and 
      administration, adverse effects, and therapeutic role of tinzaparin are reviewed. 
      Tinzaparin is a low-molecular-weight heparin (LMWH) with antithrombotic 
      properties. It has FDA-approved labeling for use in the treatment of acute 
      symptomatic deep-vein thrombosis (DVT) with or without pulmonary embolism (PE) 
      when administered in conjunction with warfarin sodium. Tinzaparin works by 
      inhibiting reactions that lead to the clotting of blood. The much-improved 
      pharmacokinetics of tinzaparin compared with unfractionated heparin (UFH) are due 
      to its lower affinity for heparin-binding proteins and endothelial cells, shorter 
      fractionated heparin chain (which allows for better bioavailability), and 
      unsaturable renal elimination. Clinical trials have demonstrated that tinzaparin 
      is at least as safe and effective as UFH for the treatment of DVT. Tinzaparin may 
      also be effective for unlabeled uses, such as prophylaxis of venous 
      thromboembolism (VTE) after orthopedic, general, and abdominal surgery, although 
      more data are needed to define the optimal dose for this indication. The 
      recommended dosage of tinzaparin for the treatment of established DVT with or 
      without PE is 175 anti-factor Xa IU per kilogram of body weight administered 
      subcutaneously once daily for at least six days until the patient achieves 
      adequate anticoagulation with warfarin. As with other LMWHs, the most common 
      complication of tinzaparin therapy is bleeding. Tinzaparin offers an additional 
      treatment option for VTE.
FAU - Neely, Jessica L
AU  - Neely JL
AD  - Eckerd Health Services, Pittsburg, PA, USA.
FAU - Carlson, Sina S
AU  - Carlson SS
FAU - Lenhart, Susan E
AU  - Lenhart SE
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 7UQ7X4Y489 (Tinzaparin)
SB  - IM
MH  - Biological Availability
MH  - Economics, Pharmaceutical
MH  - *Fibrinolytic Agents/adverse effects/pharmacokinetics/therapeutic use
MH  - Half-Life
MH  - *Heparin, Low-Molecular-Weight/adverse effects/pharmacokinetics/therapeutic use
MH  - Humans
MH  - Infusions, Intravenous
MH  - Pulmonary Embolism/*drug therapy/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Tinzaparin
MH  - Venous Thrombosis/*drug therapy/prevention & control
RF  - 38
EDAT- 2002/08/09 10:00
MHDA- 2002/09/19 10:01
CRDT- 2002/08/09 10:00
PHST- 2002/08/09 10:00 [pubmed]
PHST- 2002/09/19 10:01 [medline]
PHST- 2002/08/09 10:00 [entrez]
AID - 10.1093/ajhp/59.15.1426 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2002 Aug 1;59(15):1426-36. doi: 10.1093/ajhp/59.15.1426.